Notably, Lokshin et al. demonstrated that a multimarker panel incorporating G-CSF with CA125, CA19-9, EGFR, eotaxin, IL-2R, cVCAM, and MIF achieved a high-performance biomarker panel for early-stage ovarian cancer detection, with a sensitivity of 98.2% and a specificity of 98.7% [78]. This evidence concerns the gene MUC16 and ovarian cancer.